NTBLQ — Notable Labs Share News
0.000.00%
Last trade - 00:00HealthcareHighly SpeculativeMicro Cap
- $0.00m
- -$3.79m
- $0.31m
Brief: VBL Therapeutics Reports Full Year Loss Per Share Of $0.42
Brief: VBL Therapeutics Announces Closing Of Sale Of Manufacturing Facility and Certain Related Assets For $7.1 Million In Cash
Brief: Vascular Biogenics Applies To Transfer Listing Of Its Ordinary Shares
U.S. STOCKS ON THE MOVE-Vascular Biogenics, Apellis Pharma, Nikola
VBL Therapeutics climbs on merger
Brief: VBL Therapeutics And Notable Labs Announce Definitive Merger Agreement
Brief: Vbl Therapeutics Announces Agreement To Sell Manufacturing Facility
Vascular Biogenics Ltd reports results for the quarter ended in September - Earnings Summary
Brief: VBL Therapeutics Reports Third Quarter 2022 Financial Results
Vascular Biogenics Ltd expected to post a loss of 11 cents a share - Earnings Preview
Brief: VBL Therapeutics Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency
Vascular Biogenics Ltd reports results for the quarter ended in June - Earnings Summary
Brief: VBL Therapeutics Retained Chardan As Its Financial Advisor To Explore And Evaluate Strategic Options
Vascular Biogenics Ltd expected to post a loss of 10 cents a share - Earnings Preview
VBL Therapeutics announces job cuts, shares down
VBL Therapeutics nosedives after Ofra-Vec late-stage trial fails
Brief: VBL Therapeutics Announces Top-Line Data From Phase 3 Oval Trial Of Ofra-Vec
Vascular Biogenics Ltd reports results for the quarter ended in March - Earnings Summary
Brief: VBL Therapeutics Reports First Quarter 2022 Financial Results And Provides Corporate Update